Safety of magnetic resonance imaging contrast agents

Journal of Magnetic Resonance Imaging

Volumn 10, Issue 3, 1999, Pages 477-484

  Shellock, Frank G ^a,c   Kanal, Emanuel ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c NONE   (United States)

Author keywords

Contrast agent; Magnetic resonance imaging; MRI safety

Indexed keywords

CONTRAST MEDIUM; DIATRIZOATE; GADODIAMIDE; GADOLINIUM PENTETATE; GADOTERIDOL; IODINATED CONTRAST MEDIUM; IOHEXOL; IOPAMIDOL;

ADULT; ARTICLE; CARDIOTOXICITY; CHILD; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CROSS REACTION; DIAGNOSTIC IMAGING; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG MILK LEVEL; DRUG SAFETY; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OSMOLALITY; PREGNANCY; PRIORITY JOURNAL; SICKLE CELL ANEMIA; WILSON DISEASE;

ANIMALS; CONTRAST MEDIA; DRUG HYPERSENSITIVITY; EXTRAVASATION OF DIAGNOSTIC AND THERAPEUTIC MATERIALS; GADOLINIUM DTPA; HETEROCYCLIC COMPOUNDS; HUMANS; MAGNETIC RESONANCE IMAGING; ORGANOMETALLIC COMPOUNDS; PRACTICE GUIDELINES; SAFETY;

EID: 0032828139     PISSN: 10531807     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1522-2586(199909)10:3<477::AID-JMRI33>3.0.CO;2-E     Document Type: Article

References (78)

1. Runge VM, Wells JW. Update: safety, new applications, new MR agents. Top Magn Reson Imaging. 1995;7:181-195.
2. Oksendal A, Hals P. Biodistribution and toxicity of MR imaging contrast media. J Magn Reson Imaging 1993;3:157-65.
3. Harpur E, Worah D, Hals P, et al. Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. Invest Radiol 1993;28:S28-43.
4. Kanal E, Shellock FG. Safety manual on magnetic resonance imaging contrast agents. Cedar Knolls, NJ: Lippincott-Raven Healthcare; 1996.
5. Chang C. Magnetic resonance imaging contrast agents. Design and physiochemical properties of gadodiamide. Invest Radiol, 1993; 28(suppl 1):S21-7.
6. Cacheris W, Quay S, Rocklage S. The relationship between thermodynamics and the toxicity of gadolinium complexes. Magn Reson Imaging 1990;8:467-481.
7. Tweedle M, Eaton S, Eckelman W, et al. Comparative chemical structure and pharmacokinetics of MRI contrast agents. Invest Radiol 1988;23(suppl 1):S236-239.
8. Tweedle M. Physiochemical properties of gadoteridol and other magnetic resonance contrast agents. Invest Radiol 1992;27(suppl 1):S2-6.
9. Runge VM, Parker JR. Worldwide clinical safety assessment of gadoteridol injection: an update. Eur Radiol 1997;7(suppl 5):243-245.
10. Nelson KL, Gifford LM, Lauber-Huber C, Gross CA, Lasser TA. Clinical safety of gadopentetate dimeglumine. Radiology 1995;2: 439-443.
11. Wedeking P. Kumar K, Tweedle M. Dissociation of gadolinium chelates in mice: relationship to chemical characteristics. Magn Reson Imaging 1992;10:641-648.
12. Oudkerk M, Sijens PE, Van Beek EJ, Kuijpers TJ. Safety and efficacy of Dotarem (Gd-DOTA) versus Magnevist (Gd-DTPA) in magnetic resonance imaging of the central nervous system. Invest Radiol 1995;30:75-78.
13. Kashanian F, Goldstein H, Blumetti R, et al. Rapid bolus injection of gadopentetate dimeglumine: absence of side effects in normal volunteers. Am J Neuroradiol 1990;11:853-856.
14. Niendorf H, Dinger J, Haustein J, et al. Tolerance data of Gd-DTPA: areview. Eur J Radiol 1991;13:15-20.
15. Kanal E, Applegate G, Gillen C. Review of adverse reactions, including anaphylaxis, in 5260 cases receiving gadolinium-DTPA by bolus injection. Radiology 1990; 177(P): 159.
16. Weinmann H-J, Gries H, Speck U. Gd-DTPA and low osmolar Gd chelates. In: Runge V, ed. Enhanced magnetic resonance imaging. St. Louis: CV Mosby; 1989. p 74-86.
17. Muhler A, Saeed M, Brasch R, Higgins C. Hemodynamic effects of bolus injection of gadodiamide injection and gadopentetate dimeglumine as contrast media at MR imaging in rats. Radiology 1992;183: 523-528.
18. Weinmann H, Brasch R, Press W, Wesbey G. Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. Am J Roentgenol 1984;142:619-624.
19. Kanal E, Shellock F. Policies, guidelines, and recommendations for MR imaging safety and patient management. J Magn Reson Imaging 1992 2:247-248.
20. Akeson P, Jonsson E, Haugen I, Holtas S. Contrast-enhanced MRI of the central nervous system: comparison between gadodiamide injection and gadolinium-DTPA. Neuroradiology 1995;37:229-233.
21. Takebayashi S, Sugiyama M, Nagase M, Matsubara S. Severe adverse reaction to IV gadopentetate dimeglumine. Am J Roentgenol 1993;160:659.
22. Shellock F, Hahn P, Mink J, Itskovich E. Adverse reactions to intravenous gadoteridol. Radiology 1993;189:1-2.
23. Salonen O. Case of anaphylaxis and four cases of allergic reaction following Gd-DTPA administration. J Comput Assist Tomogr 1990; 14:912-913.
24. Tishler S, Hoffman J. Anaphylactoid reactions to IV gadopentetate dimeglumine. Am J Neuroradiol 1990;11:1167.
25. Weiss K. Severe anaphylactoid reaction after IV Gd-DTPA. Magn Reson Imaging 1990;8:817-818.
26. Tardy B, Guy C, Barral G, et al. Anaphylactic shock induced by intravenous gadopentetate dimeglumine. Lancet 1992; 339:494.
27. Omohundro J, Elderbrook M, Ringer T. Laryngospasm after administration of gadopentetate dimeglumine. J Magn Reson Imaging 1992;1:729-730.
28. Chan C, Bosanko C, Wang A. Pruritis and paresthesia after IV administration of Gd-DTPA. Am J Neuroradiol 1989:10:S53.
29. Hanquinet S, Christope C, Greef DD, Gordon P, Perlmutter N. Clinical evaluation of gadodiamide injection in paediatric MR imaging. Pedlatr Radiol 1996;26:806-810.
30. Hogstrom B, Kristoffersen DT, Lunby B, Svaland MG. Safety of gadodiamide injection in two different age groups. J Magn Reson Imaging 1996;6:255-257.
31. Ball WJ, Nadel S, Zimmerman R, et al. Phase III multicenter clinical investigation to determine the safety and efficacy of gadoteridol in children suspected of having neurologic disease. Radiology 1993; 186:769-774.
32. Niendorf H, Haustein J, Cornelius I, Alhassan A, Claus W. Safety of gadolinium-DTPA: extended clinical experience. Magn Reson Med 1991;22:222-228.
33. Sullivan M, Goldstein H. Sansone K, et al. Hemodynamic effects of Gd-DTPA administered via rapid bolus or slow infusion: a study in dogs. Am J Neuroradiol 1990;11:537-540.
34. Goldstein H, Kashanian F, Blumetti R, et al. Safety assessment of gadopentetate dimeglumine in US clinical trials. Radiology 1990; 174:17-23.
35. Hajek P, Sartoris D, Gylys-Morin V, et al. The effect of intra-articular gadolinium-DTPA on synovial membrane and cartilage. Invest Radiol 1990; 25:179-183.
36. Brasch R. Safety profile of gadopentetate dimeglumine. MRI Decisions 1989;3:13-19.
37. Hieronim DE, Kanal E, Swanson DP. Dosage of gadoteridol and adverse reactions relative to gadopentetate. Am J Health Syst Pharm 1995;52:2556-2559.
38. Berlex Laboratories. A two year report on the safety and efficacy of Magnevist (gadopentetate dimeglumine) injection. Wayne, NJ: Berlex Laboratories; 1990.
39. DeSimone D, Morris M, Rhoda C, et al. Evaluation of the safety and efficacy of gadoteridol injection (a low osmolal MR contrast agent): clinical trials report. Invest Radiol 1991;26(suppl 1):S212-216.
40. Carvlin M, DeSimone D, Meeks M. Phase II clinical trial of gadoteridol injection, a low osmolal magnetic resonance imaging contrast agent. Invest Radiol 1992;27:S16-21.
41. Runge V, Bradley W, Brant-Zawadski M, et al. Clinical safety and efficacy of gadoteridol: a study in 411 patients with suspected intracranial and spinal disease. Radiology 1991;181:701-709.
42. McLachlan S, Eaton S, DeSimone D. Pharmakokinetic behavior of gadoteridol injection. Invest Radiol 1992;27(suppl 1):S12-15.
43. Soltys R. Summary of preclinical safety evaluation of gadoteridol injection.Invest Radiol 1992;27(suppl 1):S7-11.
44. Shellock FG, Kanal E. Magnetic resonance: bioeffects, safety, and patient management. New York: Lippincott-Raven: 1996.
45. Watson A, Rocklage S. Carvlin M. Contrast agents. In: Stark D, Bradley W, eds. Magnetic resonance imaging, vol 1. St. Louis: Mosby Yearbook; 1992. p 372-437.
46. Cohan R, Leder R, Herzberg A, et al. Extravascular toxicity of two magnetic resonance contrast agents: preliminary experience in the rat. Invest Radiol 1991;26:224-226.
47. Olukoton A, Parker J, Meeks M, et al. The safety of gadoteridol injection: US clinical trial experience. J Magn Reson Imaging 1994;4:105.
48. McAlister W, McAlister V, Kissane J. The effect of Gd-dimeglumine on subcutaneous tissues: a study with rats. Am J Neuroradiol 1990;11:325-327.
49. Niendorf H, Haustein J, Louton T, Beck W, Laniado M. Safety and tolerance after intravenous administration of 0.3 mmol/kg Gd-DTPA. Invest Radiol 1991;26:S221-223.
50. Niendorf H, Laniado M, Semmler W, Schomer W, Felix R. Dose administration of gadolinium-DTPA in MR imaging of intracranial tumors. Am J Neuroradiol 1987;8:803-815.
51. Svaland MG, Lunby B, Kristoffersen DT. Comparison of the standard dose and a higher dose of gadodiamide injection for MR imaging of the central nervous system. J Magn Reson Imaging 1994;4:419-423.
52. Leander P, Allard M, Caille J, Golman K. Early effect of gadopentetate and iodinated contrast media on rabbit kidneys. Invest Radiol 1992;27:922-926.
53. Harbury O. Generalized seizure after IV gadopentetate dimeglumine. Am J Neuroradiol 1991;12:666.
54. Prince MR, Arnoldus C, Frisoli JK. Nephrotoxicity of high-dose gadolinium compared with iodinated contrast. J Magn Reson Imaging 1996;6:162-166.
55. Witte R, Anzai L. Life threatening anaphylactoid reaction after intravenous gadoteridol administration in a patient who had previously received gadopentetate dimeglumine. Am J Neuroradiol 1994; 15:523-524.
56. Runge V. Clinical application of magnetic resonance contrast media in the head. In: Runge V, ed. Contrast media in magnetic resonance imaging: a clinical approach. Philadelphia: JB Lippincott; 1992.
57. Eldevik OP, Brunberg JA. Gadopentetate dimeglumine-enhanced MR of the brain: clinical utility and safety in patients younger than two years of age. Am J Neuroradiol 1994; 15:1001-1008.
58. Hanquinet S, Christope C, Greef DD, Gordon P, Perlmutter N. Clinical evaluation of gadodiamide injection in paediatric MR imaging. Pediatr Radiol 1996;26:806-810.
59. Runge V, ed. Enhanced magnetic resonance imaging. St. Louis: CV Mosby; 1989.
60. Ekholm S, Jonsson E, Sandvik L, et al. Tolerance and efficacy of Omniscan (gadodiamide injection) in MR imaging of the central nervous system. Acta Radiol 1996;37:223-228.
61. Yoshikawa K, Davies A. Safety of ProHance in special populations. Eur Radiol 1997;7(suppl 5):246-250.
62. Haustein J, Niendorf H, Krestin G, et al. Renal tolerance of gadolinium-DTPA dimeglumine in patients with chronic renal failure. Invest Radiol 1992;27:153-156.
63. Frank J, Choyke P, Girton M, et al. Gadopentetate dimeglumine clearance in renal insufficiency in rabbits. Invest Radiol 1990;25: 1212-1216.
64. Haustein J, Niendorf H, Louton T. Renal tolerance of Gd-DTPA. A retrospective evaluation of 1,171 patients. Magn Reson Imaging 1990;8(suppl 1):43.
65. Knollmann FD, Sorge R, Muhler A, et al. Hemodynamic tolerance of intravascular contrast agents for magnetic resonance imaging. Invest Radiol 1997;32:755-762.
66. Filippi M, Rovaris M, Capra R, et al. A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials. Brain 1998;121(Pt 10):2011-2020.
67. Rofsky NM, Weinreb JC, Bosniak MA, Libes RB, Birnbaum BA. Renal lesion characterization with gadolinium-enhanced MR imaging: efficacy and safety in patients with renal insufficiency. Radiology 1991;180:85-89.
68. Munechicka H, Sullivan DC, Hedlund LW, et al. Evaluation of acute renal failure with magnetic resonance imaging using gradient-echo and Gd-DTPA. Invest Radiol 1991;26:22-27.
69. Lackner K, Krahe T, Gotz R, Haustein J. The dialysability of Gd-DTPA. In: Bydder G, Felix R, Bucheler E, eds. Contrast media in MRI. Bussum: Medicom Europe; 1990. p 321-326.
70. Tweedle MF, Eckelman WC, Wedeking P. Pharmacokinetics and metabolism of 153 gadolinium complexes. Labelled Comp Radiopharm 1986;23:1347-1348.
71. Schmiedl U, Maravllla K, Gerlach R, Dowling C. Excretion of gadopentetate dimeglumine in human breast milk. Am J Roentgenol 1990;154:1305-1306.
72. Rofsky N, Weinreb J, Litt A. Quantitative analysis of gadopentetate dimeglumine excreted in breast milk. J Magn Reson Imaging 1993;3:131-132.
73. Brody A, Sorette M, Gooding C, et al. Induced alignment of flowing sickle erythrocytes in a magnetic field. Invest Radiol 1985;20:560-566.
74. Brody A, Embury S, Mentzer W, Winkler M, Gooding C. Preservation of sickle cell blood flow patterns during MR imaging. An in vivo study. Am J Roentgenol 1988;151:239-241.
75. American College of Radiology. Manual on iodinated contrast media. American College of Radiology; 1991.
76. Atkinson T, Kaliner M. Anaphylaxis. Clin Allergy 1992;76:841-855.
77. Fiddian-Green R, Haglund U, Gutierrez G, Shoemaker W. Goals for the resuscitation of shock. Crit Care Med 1993;21:325-31.
78. Yunginger J. Anaphylaxis. Ann Allergy 1992;69:87-96.